Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684447 · ClinicalTrials.gov registry record · Phase 2
Neural and Antidepressant Effects of Propofol
A Phase 2 study of Treatment-Resistant Depression, sponsored by University of Utah.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT03684447: Active Phase 2 study of Treatment-Resistant Depression, sponsored by University of Utah.
NCT03684447 is a Phase 2 study of Treatment-Resistant Depression that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 48 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03684447, a Phase 2 study of Treatment-Resistant Depression, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the antidepressant effects of propofol at two different doses while measuring potential treatment-related biomarkers.
Conditions Studied
Interventions
- DRUG Propofol
Study Locations (1)
Utah
- University Neuropsychiatric Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-04-21 |
| Est. Completion | 2024-07 |
| Phase | Phase 2 |
What the registry record for NCT03684447 still lists
NCT03684447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Propofol is the first listed.
NCT03684447 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT03684447 about?
NCT03684447 is a clinical study titled "Neural and Antidepressant Effects of Propofol". This study will compare the antidepressant effects of propofol at two different doses while measuring potential treatment-related biomarkers.
What is the current status of trial NCT03684447?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2019-04-21. Estimated completion is 2024-07.
What conditions does trial NCT03684447 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT03684447?
The interventions under investigation include: Propofol (DRUG).
Who is sponsoring clinical trial NCT03684447?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03684447 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03684447's enrollment target sits among peer trials
48 30th of 54 higher than 25 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
-
Psilocybin rTMS for Treatment Resistant Depression
RECRUITING · Phase 2
-
Antidepressant Effects of Nitrous Oxide
RECRUITING · Phase 2
-
Mindfulness Engaged Neurostimulation for Depression
RECRUITING · Phase 2
-
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
ACTIVE NOT RECRUITING · Phase 2
-
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI